Paper40720060
Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.
de Castro C and 14 others. Adv Ther, 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan. Papers, record 40720060. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40720060
- Disease
- paroxysmal nocturnal hemoglobinuria33 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hemoglobinuria, Paroxysmal | Major topic |
| Antibodies, Monoclonal, Humanized | Major topic |
| Complement C3 | Major topic |
| Complement Inactivating Agents | Major topic |
| Humans | |
| Male | |
| Female | |
| Middle Aged | |
| Adult | |
| Treatment Outcome | |
| Aged | |
| Hemoglobins | |
| Complement C5 | |
| Bilirubin | |
| Reticulocyte Count |
Source PubMed
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03500549 | Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT03531255 | Pegcetacoplan Long Term Safety and Efficacy Extension Study | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT04085601 | A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH | Derived from the trial | Yes | ClinicalTrials.gov |
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38071133 | Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape. | Blood Rev | 2024 | https://conductscience.org/library/papers/38071133 | PubMed |
| 2 | 36532073 | Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan. | Front Immunol | 2022 | https://conductscience.org/library/papers/36532073 | PubMed |
| 3 | 11900238 | Fatigue in cancer patients compared with fatigue in the general United States population. | Cancer | 2002 | https://conductscience.org/library/papers/11900238 | PubMed |
| 4 | 23610373 | Thrombosis in paroxysmal nocturnal hemoglobinuria. | Blood | 2013 | https://conductscience.org/library/papers/23610373 | PubMed |
| 5 | 37707673 | Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report. | Adv Ther | 2023 | https://conductscience.org/library/papers/37707673 | PubMed |
| 6 | 39734592 | Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators. | Ther Adv Hematol | 2024 | https://conductscience.org/library/papers/39734592 | PubMed |
| 7 | 33512400 | How I treat paroxysmal nocturnal hemoglobinuria. | Blood | 2021 | https://conductscience.org/library/papers/33512400 | PubMed |
| 8 | 19179465 | Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. | Blood | 2009 | https://conductscience.org/library/papers/19179465 | PubMed |
| 9 | 7566002 | Natural history of paroxysmal nocturnal hemoglobinuria. | N Engl J Med | 1995 | https://conductscience.org/library/papers/7566002 | PubMed |
| 10 | 30442279 | General Population Norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale. | Value Health | 2018 | https://conductscience.org/library/papers/30442279 | PubMed |
| 11 | 37994576 | Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health-related quality of life and productivity. | Eur J Haematol | 2024 | https://conductscience.org/library/papers/37994576 | PubMed |
| 12 | 36732204 | Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition. | Blood Rev | 2023 | https://conductscience.org/library/papers/36732204 | PubMed |
| 13 | 36848639 | Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. | Blood Adv | 2023 | https://conductscience.org/library/papers/36848639 | PubMed |
| 14 | 38812989 | Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings. | Res Pract Thromb Haemost | 2024 | https://conductscience.org/library/papers/38812989 | PubMed |
| 15 | 34386754 | Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. | EClinicalMedicine | 2021 | https://conductscience.org/library/papers/34386754 | PubMed |
| 16 | 20145265 | Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. | Haematologica | 2010 | https://conductscience.org/library/papers/20145265 | PubMed |
| 17 | 35830642 | Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35830642 | PubMed |
| 18 | 38142401 | Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria. | Blood | 2024 | https://conductscience.org/library/papers/38142401 | PubMed |
| 19 | 38315872 | Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH. | Blood Adv | 2024 | https://conductscience.org/library/papers/38315872 | PubMed |
| 20 | 38348608 | Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. | Am J Hematol | 2024 | https://conductscience.org/library/papers/38348608 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42636034 | Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-naïve and -experienced patients with paroxysmal nocturnal hemoglobinuria. | J Comp Eff Res | 2026 | https://conductscience.org/library/papers/42636034 | PubMed |
| 42319133 | Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and Hurdles. | Eur J Immunol | 2026 | https://conductscience.org/library/papers/42319133 | PubMed |
| 42185224 | Pegcetacoplan Delivers Real-World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real-World Clinical and Patient-Reported Outcomes. | Eur J Haematol | 2026 | https://conductscience.org/library/papers/42185224 | PubMed |
| 41596089 | Redox Regulation of Complement Pathway Activation in Aging and Related Diseases. | Antioxidants (Basel) | 2025 | https://conductscience.org/library/papers/41596089 | PubMed |
| 41348037 | The varieties of therapeutic experience: navigating treatment options for patients with PNH. | Hematology Am Soc Hematol Educ Program | 2025 | https://conductscience.org/library/papers/41348037 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| PEGCETACOPLAN | CHEMBL4298211 | Derived from the trial | 3 | https://conductscience.org/library/drugs/CHEMBL4298211 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40720060
GET https://conductscience.org/api/papers/v1/40720060/references?page=2